Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation

American Journal of Transplantation

Volumn 13, Issue 10, 2013, Pages 2653-2663

  Perrin, P ^a   Caillard, S ^a   Javier, R M ^a   Braun, L ^a   Heibel, F ^a   Borni Duval, C ^a   Muller, C ^a   Olagne, J ^a   Moulin, B ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Bone mineral density; bone turnover markers; fracture; hyperparathyroidism; hypophosphatemia; kidney transplantation

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CINACALCET; CORTICOSTEROID; CYCLOSPORIN A; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; TACROLIMUS;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRACTURE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

BONE MINERAL DENSITY; BONE TURNOVER MARKERS; FRACTURE; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION;

ADULT; AGED; CALCIFICATION, PHYSIOLOGIC; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARATHYROID HORMONE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84884903740     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12425     Document Type: Article

References (52)

1. Abbott KC, Oglesby RJ, Hypolite IO, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol 2001; 11: 450-457.
2. Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014-3018.
3. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ., Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994; 58: 912-915.
4. Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N., Risk of fractures after renal transplantation in the United States. Transplantation 2009; 87: 1846-1851.
5. Nikkel LE, Mohan S, Zhang A, et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant 2012; 12: 649-659.
6. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B., Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999; 67: 1218-1222.
7. O'Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL., Risk factors for fractures in kidney transplantation. Transplantation 2002; 74: 362-366.
8. Opelz G, Dohler B., Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. Transplantation 2011; 91: 65-69.
9. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S100-S110.
10. Akaberi S, Lindergard B, Simonsen O, Nyberg G., Impact of parathyroid hormone on bone density in long-term renal transplant patients with good graft function. Transplantation 2006; 82: 749-752.
11. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N., Bone loss after renal transplantation: Role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000; 14: 457-463.
12. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N., Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17: 268-274.
13. Lim WH, Coates PS, Russ GR, Coates PT., Hyperparathyroidism and vitamin D deficiency predispose to bone loss in renal transplant recipients. Transplantation 2009; 88: 678-683.
14. Setterberg L, Sandberg J, Elinder CG, Nordenstrom J., Bone demineralization after renal transplantation: Contribution of secondary hyperparathyroidism manifested by hypercalcaemia. Nephrol Dial Transplant 1996; 11: 1825-1828.
15. Roe SD, Porter CJ, Godber IM, Hosking DJ, Cassidy MJ., Reduced bone mineral density in male renal transplant recipients: Evidence for persisting hyperparathyroidism. Osteoporos Int 2005; 16: 142-148.
16. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366.
17. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L., Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321: 598-602.
18. Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E., Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006; 1: 1300-1313.
19. Egbuna OI, Taylor JG, Bushinsky DA, Zand MS., Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007; 21: 558-566.
20. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y., Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004; 19: 1281-1287.
21. Reinhardt W, Bartelworth H, Jockenhovel F, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998; 13: 436-442.
22. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S93-S96.
23. Giannini S, D'Angelo A, Carraro G, et al. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol 2001; 56: 353-363.
24. Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341-348.
25. Boom H, Mallat MJ, de Fijter JW, Paul LC, Bruijn JA, van Es LA., Calcium levels as a risk factor for delayed graft function. Transplantation 2004; 77: 868-873.
26. Ozdemir FN, Afsar B, Akgul A, Usluogullari C, Akcay A, Haberal M., Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients. Transplant Proc 2006; 38: 480-482.
27. Lewin E, Olgaard K., Influence of parathyroid mass on the regulation of PTH secretion. Kidney Int Suppl 2006; 102: S16-S21.
28. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of WHO Study Group. World Health Organ Tech Rep Ser 1994; 1-129.
29. Gaspari F, Perico N, Matalone M, et al. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 1998; 9: 310-313.
30. Caravaca F, Fernandez MA, Ruiz-Calero R, et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998; 13: 2605-2611.
31. Ambuhl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U., Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: Impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999; 34: 875-883.
32. Van de Cauter J, Sennesael J, Haentjens P., Long-term evolution of the mineral metabolism after renal transplantation: A prospective, single-center cohort study. Transplant Proc 2011; 43: 3470-3475.
33. Torres A, Rodriguez AP, Concepcion MT, et al. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13: 94-97.
34. Giannini S, Sella S, Silva Netto F, et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: Role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res 2010; 25: 841-848.
35. Drechsler C, Grootendorst DC, Boeschoten EW, Krediet RT, Wanner C, Dekker FW., Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients. Nephrol Dial Transplant 2011; 26: 1340-1346.
36. Grethen E, Hill KM, Jones R, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab 2012; 97: 1655-1662.
37. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y., Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7: 1193-1200.
38. Shalhoub V, Ward SC, Sun B, et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 2011; 89: 140-150.
39. Casez JP, Lippuner K, Horber FF, Montandon A, Jaeger P., Changes in bone mineral density over 18 months following kidney transplantation: The respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002; 17: 1318-1326.
40. Kanaan N, Claes K, Devogelaer JP, et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol 2010; 5: 1887-1892.
41. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM., PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156.
42. Bover JCM., Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: New insights into vitamin D receptor activation. Kidney Int Suppl 2011; 1: 122-129.
43. Chen TL, Feldman D., Glucocorticoid receptors and actions in subpopulations of cultured rat bone cells. Mechanism of dexamethasone potentiation of parathyroid hormone-stimulated cyclic AMP production. J Clin Invest 1979; 63: 750-758.
44. Akaberi S, Simonsen O, Lindergard B, Nyberg G., Can DXA predict fractures in renal transplant patients ? Am J Transplant 2008; 8: 2647-2651.
45. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676.
46. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530-1537.
47. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
48. Yu RW, Faull RJ, Coates PT, Coates PS., Calcium supplements lower bone resorption after renal transplant. Clin Transplant 2012; 26: 292-299.
49. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM., Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
50. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494.
51. Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM., Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008; 86: 413-417.
52. Cho ME, Duan Z, Chamberlain CE, Reynolds JC, Ring MS, Mannon RB., Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant Proc 2010; 42: 3554-3558.